Azelaic Acid
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Azelaic Acid: From Acne and Rosacea to Seborrheic Dermatitis
One-Sentence Summary
Azelaic acid is a topical agent originally used to treat acne and rosacea. The TxGNN model predicts a top-ranked new indication of demodicidosis of sebaceous gland, but that prediction has no supporting studies. The best-supported candidate in the data compiled for this report is seborrheic dermatitis, with 1 Phase 2 clinical trial (results not provided) and 10 publications, mostly reviews.
Quick Overview
The table follows the top-ranked prediction (rank 1) as the template requires. Seborrheic dermatitis (rank 7) is the only candidate with a clinical trial, so it is discussed in the evidence sections below.
| Item | Content |
|---|---|
| Original Indication | Acne and rosacea (from the knowledge graph; the Singapore licence text is blank) |
| Predicted New Indication | Demodicidosis of sebaceous gland (rank 1) |
| TxGNN Prediction Score | 98.05% |
| Evidence Level | L5 (model prediction only) |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
For comparison, the best-supported candidate:
| Item | Seborrheic dermatitis (rank 7) |
|---|---|
| TxGNN Prediction Score | 93.53% |
| Evidence Level | L2 (one completed Phase 2 randomised, vehicle-controlled pilot; results not provided) |
| Recommended Decision | Proceed with Guardrails (research question only) |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for azelaic acid is not available in the data compiled for this report. Published reviews describe it as having anti-infective and anti-inflammatory activity. It also inhibits follicular keratinization and epidermal melanogenesis (PMID 26355614).
Demodicidosis (rank 1): Azelaic acid is used in rosacea, where Demodex mite density is implicated. This link is speculative, as no trials or literature were provided.
Seborrheic dermatitis (rank 7): This is the most plausible candidate. The condition involves Malassezia, inflammation and sebaceous activity. Azelaic acid has anti-inflammatory and antimicrobial effects, and it is already used in the related condition rosacea. Seborrheic dermatitis often co-occurs with rosacea and acne. One case report describes managing both conditions together. However, a 1989 clinical pharmacology study found that a 20% cream did not change seborrheic skin in healthy-looking epidermis, although it improved acne lesions (PMID 2475995). This is a cautionary signal.
Keratinization disease (rank 6): There is indirect preclinical support. Azelaic acid reduces keratinocyte proliferation in vitro and has anticomedonal effects. This evidence concerns comedonal hyperkeratosis, not a defined keratinization disorder.
Other predictions (cutaneous candidiasis, familial lichen planus, elevated plasma zinc, adermatoglyphia, nail infection, tinea corporis, Beare-Stevenson syndrome) have no direct supporting evidence. Several, such as elevated plasma zinc, adermatoglyphia and Beare-Stevenson syndrome, are likely graph artifacts.
Clinical Trial Evidence
Only seborrheic dermatitis has a registered trial. The other nine predictions have none.
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT00408330 | Phase 2 | Completed | 48 | Double-blind, randomised, vehicle-controlled, 6-week pilot of azelaic acid 15% gel for mild to moderate facial seborrheic dermatitis. Results not provided, so efficacy cannot be confirmed. |
Literature Evidence
The table covers the seborrheic dermatitis candidate and the most relevant mechanistic papers. No RCTs were retrieved.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 26355614 | 2015 | Review | J Drugs Dermatol | Evidence-based update on azelaic acid's mechanisms (anti-infective, anti-inflammatory, antikeratinizing) and its clinical uses |
| 19213227 | 2009 | Review | J Drugs Dermatol | Current status and therapeutic horizons of facial seborrheic dermatitis, which often coexists with rosacea and acne |
| 2475995 | 1989 | Clinical pharmacology study | Acta Derm Venereol Suppl | 20% cream improved acne lesions but caused no detectable change in normal or seborrheic epidermis, and no specific change in sebum composition or excretion |
| 35751534 | 2022 | Review | Acta Dermatovenerol Alp Pannonica Adriat | Malassezia virulence factors (including azelaic acid production) in skin disorders |
| 21278898 | 2011 | Case report | J Clin Aesthet Dermatol | Rational management of papulopustular rosacea with concomitant seborrheic dermatitis |
| 2473140 | 1989 | In vitro study | J Invest Dermatol | Azelaic acid decreased DNA synthesis in mouse keratinocytes in a dose- and time-dependent manner |
| 8935627 | 1996 | Animal study | J Dermatol | 20% azelaic acid acted on experimentally induced comedones in rabbits |
| 19744410 | 2009 | Review | J Fam Pract | General review of minor skin ailments (nail infection); azelaic acid is effective for rosacea, with no specific nail evidence |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN07138P | SKINOREN CREAM 20% | Cream | Not stated in the available data |
The only registration is a valid single-ingredient topical cream.
Safety Considerations
- Contraindications (from the knowledge graph, not label text): dermatitis, Wilson disease, iron metabolism disease, hereditary hemochromatosis, hypopigmentation of the skin, and pigmentary dilution. The "dermatitis" entry deserves attention given the seborrheic dermatitis candidate.
- Drug Interactions: Three interactions were recorded (salbutamol, levothyroxine, niacin). Their severity levels are unknown.
Please refer to the package insert for warnings and label contraindications.
Conclusion and Next Steps
Decision: Hold (top-ranked prediction and overall). Proceed with Guardrails applies only to seborrheic dermatitis, as a research question.
Rationale:
- Eight of the ten predictions rest on model scores alone or on general reviews with no direct azelaic acid evidence.
- Seborrheic dermatitis is the only candidate with a trial. It is a small Phase 2 pilot (n=48) with no available results. The knowledge graph also lists dermatitis as a contraindication, and an older study found no effect on seborrheic skin.
To proceed, the following is needed:
- Results of NCT00408330 (efficacy and tolerability versus vehicle)
- The Singapore package insert, to confirm warnings, contraindications and the approved indication text
- Reconciliation of the knowledge-graph "dermatitis" contraindication with the seborrheic dermatitis use
- Mechanism-of-action data (for example from DrugBank)
- Interaction severity details for the three recorded drug interactions
- For demodicidosis, any clinical or in vitro data on Demodex before it is further considered
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.